NCT05205499View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease

NAActive, not recruitingINTERVENTIONAL
Enrollment

1,059

Participants

Timeline

Start Date

March 10, 2022

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2028

Conditions
Coronary Artery Disease
Interventions
DEVICE

Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System

Subjects in this arm will be treated with IBS

Trial Locations (1)

Unknown

Fuwai Yunnan Cardiovascular Hospital, Kunming

All Listed Sponsors
lead

Biotyx Medical (Shenzhen) Co., Ltd.

INDUSTRY